Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

Findings from BOREAS and NOTUS showed dupilumab significantly reduced moderate to severe acute COPD exacerbations vs placebo. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, shares the latest clinical discoveries from the BOREAS trial on type 2 inflammation in patients with chronic ...

Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that causes inflammation and lung damage. Lifestyle changes such as an anti-inflammatory diet and supplements can help manage ...

WAYNETOWN, Ind. — Tony Manion doesn't miss a workout. Seriously. Three hours a day, every day. "You just make a choice to do it," Manion said, between reps from his home gym in rural Montgomery County ...

Lung disease is a general term for several disorders that include airway diseases, lung tissue diseases, and lung circulation diseases, some of which may lead to respiratory failure. During the course ...